Price Target Update on Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) : 2 investment research analysts covering Sanofi (NYSE:SNY) have an average price target of $55.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $58 and the lowest target is $53 for the short term. Analysts expect the variance to be within $3.54 of the average price.

Other Equity analysts have also commented on the company shares. Equity analysts at the Brokerage firm Barclays upgrades its rating on Sanofi (NYSE:SNY). The rating major has initiated the coverage with overweight rating on the shares. Earlier, the shares were rated a Equal-weight by the brokerage firm. The rating by the firm was issued on May 12, 2016.

Sanofi (NYSE:SNY): stock turned positive on Thursday. Though the stock opened at $40.98, the bulls momentum made the stock top out at $41.29 level for the day. The stock recorded a low of $40.51 and closed the trading day at $41.19, in the green by 2.23%. The total traded volume for the day was 2,842,941. The stock had closed at $40.29 in the previous days trading.

The company shares have dropped -21.75% from its 1 Year high price. On Aug 10, 2015, the shares registered one year high at $54.98 and the one year low was seen on Jun 16, 2016. The 50-Day Moving Average price is $39.89 and the 200 Day Moving Average price is recorded at $40.90.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.